was reduced 35% by treatment with a chimeric antii to the G? IIb/IIIa integrin as compared with treatment with placebo (15). 'lhis bene6cial et&t was achieved at the expense of a 15% incidence of hemonhage requiring blood tramfusion. Tii is a new mmpeptide tymsine derivative antagor&t of the RGD binding site on the platelet GP IIb/IIIa receptor that has demousttated antikomhotk etlicaq in auimal models of thrombosis (16) . Preliminary studies with this agent in humans (17, 18) have demonstrated a dose-related inhibii of platelet fumxionandprokmgationofbieedmgtimeinnormalvohmteea Accordingly, the purpose of this mr&m&xk dmrbleblimt pkiahxontroUed dose-ran& shdy was 1) to examine thesafetyandtoIerabilityofti&ibangiveninconjun&onwith hepin and aspirin in higb risk patients undergoing angioplasty, 2) to study the pharmacodynamics and @rmaa&met-icSoftiro6baninconjmxtionwithheparinandaspirin,and3) to evahtate the incidence of adverse cardiac outcomes (urgent repeat revasdarization, nonhtai myocardial infarction and deatb) witb tiro6ban versus placebo during the subsequent hospital stay.
Tbk study was designed spedbUy to develop a rational tiroliban dosing regimen during angioplasty and to prcwide preliminaryevidenceofthesafetyandefficacyofuseofthis regimen.
M&hOdS
Wpeti-h=J eard&ntui&a.Thistrialwasa m&center, randomized double blind, placebocontrolled k-ranging study amducfed in nine clinical centers (see Appendix). Patients eligiie for study enrollment included men and women 118 and ~75 years of age who were scheduled to undergo coronary ang@lasty for treatment of 1) rest angina pectoris [onset witbin 5 days of angiopMy], 2) recurrent angina [r24 h and <5 days after myocardial infarction], or 3) complex coronary lesion morphology asccciated with a moderate to high risk of praxduml failure as descrii by the American Heart Association/American College of Cardiology (AHA/ACC) Task Force on Coronary Angioplasty (19) and mod&d by Ellis et al. (20) . This category included patients with AHA/ACC type B or type C target lesion mo@ology. !Specik exclusion criteria included women of childbearing potential, and patients who had thrombolytic theran within 24 b of angioplasty, severe ditIuse multivessel coronary atherosclerosis, unamtroUed cardiac adythmih past or present Needing disorder or increased bleeding risk, history of stroke or other intracranial pathology, severe congestive heart failure or hemodynamic instability and allergy or intolerance to aspirin or heparin.
'%is study was approved by the institutional review board of each institution and informed consent was obtained from each patient. Alter coronary art*, patients were observed during the remainder of their hospital stzy for chnical outcome and bleeding complications.
AnglopIasty pmcedore. All patients received aspirin (325 mg orally) before angioplasty, and intravenous heparin (initial bolus 1OJlOO U; subsequent bohrses of 2JKltl U) was administered during the procedure to achieve a target inlaboratory activated dotting time of 300 to 350 s A comirmous intravenous infu&m of heparin (1,008 U/h) was initiated after at@op&ytoachieveatargetactivatedpartialthromboplastin time of 60 to 80 s. Weight adjustment of heparin therapy for patients weighing <75 kg was pre+c&d in the protocol. In these patients the initial bohts of heparin was limited to 150 U/kg body weight and the infusion to 15 U/kg per h. Either activestudydrugorplacebowasrtdmi&eredimmediately afterthecoronaryguidewirecrossedthestenoskAcontinuousinfu&mofstudydrugorplaceboandheparinwasthen admhktered for 16 to 24 h after the ar@op&y procedure, at which time these agents were discontinued simultaneously. Vascular access sheaths were removed 4 h after discontinuationofintravenousheparinandstudydrug Treatment aIbwhL Tbree dose regimens of timtIban were studied in three sequential panels. Patients within each panel were randomiaed to receive either tiroliban or placebo in a 3:l randomization design. Iabomtoty stedks. The pbarmaoodynamic effect of tirofi . ban on bleeding time and ex vivo platelet aggregation in respom to 5 -l/liter adenosine diphosphate (ADP) were evaluated before and after study drug administration. Blood was collected in 3.8% sodium citrate tubes, and platelet aggRgation was measured hy tbe turbidimetric method using 5 ml/liter ADP. Platelet aggregation was quantified as the maximalchangeinlighttram&&noccurrmgwithin5mincf addition of agonist. Posttnxtment platelet aggregation was expressed as a percent of each patient's pretreatment level of aggregation. Data were reported as percent inhibition of aggregation. Bleeding times were determined by the template technique of Ivy et al. (21) as performed by an automated &+&-Jl-ma&g insmment (!&plate II, C&anon Teknika Corporation). Bkeding times ~30 min were truncated and the measurement was reported as 30 min. Bleeding time data are reported as fold-extension (bleeding time at 2 h/bleeding time at baseline). cliaial and pa&s. AU patients were observed for adverse chical outcome of the ar@opMy procedure, including death, need for urgent repeat revascularization or nonfata! myocardial infarction within 24 h of the procedure and during the subsequent hospital stay. Angioplasty success was defined as final v&ally assessed diameter percent stenosis <50% in the absence of any of these adverse outcomes. Major bleeding complications were defined as 1) 25.0 g/d) decrease in hemo glohin, 2) need for packed red bloud cell transfusion. 3) corrective vascular surgery, 4) intracraniai or retroperitoneal hemorrbage, or 5) hemorrhage requiring discontinuation of thcstudydruginanattempttoachievebemostasis (56) 7(1') 3: (44) 23 (32) 17 (2.3 l (1) 6 (8) Plac - 12 WV 6W 2 (10) II (55) 3 (15) 3 ( Statistiepl analysis. Descriptive statistics for population demographics include frequency counts and means and standard deviations for continuous variables, with data from the patients receiving tirofiban and those receiving placebo each pooled across all three panels. Inhibition of ADP-mediated platelet aggregation and bleeding times are described (fcr each panel) as median, mean, lOth, 25th, 75th and 90th percentiles. Due to the nonnormality of the platelet inhibition data resulting from the almost complete response (100% inhibition of ADP-mediated aggregation) of subjects receiving higher doses of tirofiban, an ad hoc Jonckheere-Terpstra test for increasing trend with dose was conducted. A Wilcoxon rank sum test was used to test the difference from placebo at each dosage level of tirofiban, for both inhibition of platelet aggregation and bleeding time extension. All p values provided potentially overstate the level of significance because they were not adjusted for multiple comparisons, given the absence of prespecified hypothesized comparisons in the protocol (the focus of the trial was on estimation rather than formal hypothesis testing). Because of the very small sample size (about 20 patients/ group), the trial had little power to detect a clinically meaningful reduction (33% reduction) in clinical events between the tiroliban and placebo groups. For example, if the majc,r adverse clinical event rate was 15% in the heparin group, with 20 patientslgroup there is only 5% power to detect a statistically sign&ant (p = 0.05) reduction in event rate to 10%. Therefore, no formal comparative statistics were performed.
Results
Study patients. Baseline patient demographics are summarized in Table 1 for the 73 patients receiving tirofiban and the 20 patients who received placebo. Approximately 48% of patients were enrolled on the basis of complex coronary lesion morphology alone.
Pharmeeodpami responses. The median percent inhiiition of ex vivo platelet aggregation in response to 5 WI/liter ADP as well as median bleeding times at 2 h of study drug infusion are shown in Table 2 . The inhibition of platelet aggregation was rapid in onset with 93% to %% inhibition observed 5 min after administration of the tirofiban bolus in panels I1 and 111, respectively. Inhibition of platelet aggregation was sustained during continuous intravenous infusion of tirofiban and was most marked at the higher dose panels II and 111 (Fig. IA) . The increase in inhibition with increasing dose levels of tirofiban at 5 min, 2 h and end of the infusion was highly significant (p < 0.001 by the Jonckheere test). No inhibition of platelet aggregatior was noted in patients receiving heparin only (placebo); the difference between tirofiban doses and placebo at all time points was also highly sign&ant (p < 0.001). Although no effect of heparin on ex vivo platelet aggregation was seen, there was a 2.1-fold rise (to 11 min) in the median bleeding time observed at 2 h of treatment in the placebo group. The median increase in panel I was 2.9-fold (to 19.5 min) (p = 0. Fig. 1B) . Inhibition of platelet aggregation resolved rapidly after cessation of tirofiban, and median values at 0.5,15,4 and 8 h after infusion are shown for all panels in Figure 2 When vascular access sheaths were removed 4 h after cessation of tbe study drug infusion, the percent inhibition of aggregation was ~50% for all peels.
Advem?cIinkdThere were no deaths, myocardial infarctions or emergency coronary bypass operations in this trial. The incidence of urgent recatheterization or repeat coronary angioplasty. or both, is shown in Table 3 . 'The need for revascutarization was very low both during study drug infusion and before hospital discharge. Although repeat revascularization appeared to be less frequent during study drug infusion (27% in patients treated with tirofiban vs. 5.0% in those given placebo) the incidence was so infrequent (less than one patient in each panel) that no formal statistical comparison was made.
HeprorrBpge. nere were no corrective vascular operations or intracranial or retroperitoneal hemonhages in this trial. One patient in tirofiban panel III received 1 U of packed red blood cell transfusion and one patient in the placebo group received 2 U of packed red blood cell transfusion. The majority of "events" comprised discontinuation of study drug secondary to the occurrence of vascular access site hematoma or excessive oozing lo allow sheath removal and hemostasis. 'The overall incidence of bleeding events was 4.8%, 3.3%, 13.6% and 5.0% in treatment panels I, II and III and the placebo group, respectively. Study drug was discontinued in one patient in panel III with gingival bleeding who manifested a sign&ant decrease in hematocrit that was later determined to be spurious in origin. One patient who mamfested thrombocytopenia with a count of 70,000/mm3 during study drug infusion had spontaneous recovery of the platelet count to 93,0Wnm3 after intravenous heparin was discontinued, despite the continued infusion of tirofibau for 12 additional h.
Discussion
Pku.maadpmIcs. 'Ilk double-blind random&l, placebocontrolled dose-r.mging study is ,he first to evaluate the novel nonpeptide platelet GP IIb/IIIa receptor antagonist tirofiban as a prophylactic adjunct to coronary angioplasty in a high risk subset of patients. In this trial, tirofiban demonstrated a dose-dependent Inhibition of ex vivo platelet aggregation in rcvnse to 5 pmol/liter ADP that was very rapid in onset and was susta~! by r continuous intravtnous infusion of the drug. fnhibition of platelet aggregation at 5 min after a lO-CLgflrp Mua dose of tirofiban exceeded 90%. Previous studies in both aimal models and humans have suggested that suppression of ADP-induced platelet aggregation to ~20% of baseline is a suitable target for pharmacologic efficacy of GP IIb/IIIa recep ICI a?. Igonists. This level of antiaggregatory activity has been shown tw prevent p!atelet thrombosis in animal models of severe &ionary stenosis (13, 14, 22, 23) and to reduce ischemic adverse outcomes after high risk coronary angioplasty in humans (12, 24) . Be&use a high level of inhibition (>9O%) was seen at the dosing regimen utilized in panel 11 (10 pg/kg and 0.10 &kg per min infusion), the highest dose regimen was not associated with greater platelet antiaggregatory activity, though there did appear to be more consistent inhibition across the population studied (see Fig. 1A ). However, the occurrence of hemorrhagic events was increased in patients receiving this high dose, suggesting that, with relatively constant (albeit high) heparin dosing, high levels of inhibition with a GP IIb/IlIa blocker could contribute to an increase in such events. Although bleeding times were elevated in both of the higher dose panels (>30 mir. at 2 h), it is possible that the use of a higher concentration of ADP or a more potent agonist, such as thrombin receptor-activating peptide, might have allowed further separation of tbe antiaggregatory effects of these doses. If this were the case. it might help to explain the Mettnces in the hemorrhagic event rates between the panels II and 111.
The rapid cessation of platelet inhibition after &amtinu-ation of tirofiban is consistent with its relatively short half-life of 1.7 h (17,18). Thr percent inhibiiion of platelet aggregation was <50?6 fcr all dose panels of tirofiban 4 h after drug discontinuation. 'I'M short half-lie due to reversible binding of the GP IIb/lIIa receptor may have important safety implications, particularly in patients who require emergency corn nary bypass surgery or who have bleeding at the femoral access site after coronary angioplasty. Recovery in platelet funaioo adequate to allow vasculti and wound bemo&-& can be expected to occur within 4 h of cessation of tiroliban.
Adverse events. Treatment with tirofiban appears to be well tolerated. The increase in hemorrhagic events seen at the highest dose studied (panel III) was largely related to hemorrhage at the vascular access site. Only one patient (1.4%) who received tirofiban in this study required red cell tra&us& This low incidence of hemorrhage was observed despite the lack of rigorous weight adjustment in heparin dosii Bleeding complications during IIb/IIIa receptor blockade therapy have been correlated with both maximal in-laboratory activated clotting time and total relative heparin dose (253). Recent data (25-27) have suggested that the need for blood transfL sion in patients receiving the GP lIb/lIIa receptor blocking agent c7E3 may be reduced by limiting the initial heparin bolus to 70 U/kg without subsequent adjustment based on activated clotting time measurement. As the pre;ent study utilized a relatively high dose regimen of intravenous beparin with weight adjustment to 150 U/kg for the initial bol rs only in patients weighing ~75 kg, more stringent weight adjustment of heparin dosing might have further reduced the incidence of hemorrhage in this trial. Preliminary data from a pilot trial of c7W therapy during coronary angioplasty (26) suggest that a strategy of rigorous weight adjustment oi heparin (W to 1CKWkg bolus) and early vascular access sheath removal (after cessa!ion of heparin) may substantially reduce bleeding complications and the need for blood transfusii.
The incidence of adverse ischemic clinical outcomes in this trial was low. No patient required emergency bypass surgery or sustained a myocardial infarction. The need for urgent revascularizatiorl was low, occufcin8 in one patient or none in each panel stud;ed. Formal statistical analyses were not applied to these 0utaHne data because of the small sample size. These results compare favorably with the expected 10% to 20% rate of ischemic complications previously observed in patients with . 27, No. (29) suggest that complex coronary lesion mcrphobgy alone may be a less pcwerfd pre%tor of benefkial outcome after coronary an* phsty in patients treated with GP Ifb/UIa receptor blockade than is the clinical presentation of unstable angina. This cbservation is am&tent with the more dramatic reducthn in adverse ischemic outames after angioplasty observed in patientswbopresentwithachicalsyndmmeofunstableangina than in those who present stable angina (30). Because almost haIf cf patients in tbe present sh@ were enrolled cn the basii of criteria of ~rmplex coron3ry lesion morphology alone (Tabk1).omgroupmighthaveanoverallk3serdcgreeof benefit from GP IIb/Ua receptor !hckade after coronary W+WW-CesdPslosa Aitbough determiaation of tbe overall efficaq of tirofiban in reduciug early and late ischemk complications tier angioplasty must await a larger scale trial, this study is the first to establish a rational and saJe dosing regimen for this agent. After a bolus dose of 10 p,jlJ(g and a continuous infusioncf0.!0clglkglmin,tircfibanresldtsinrapidand profoud inhiiition of platelet aggregation and a low risk of asscciated hemorrhage or need for blood transfusion. The extremely low incidence of ischemic outcomes (death, myocardial infarction, repeat -tion) cbselved ill this trial precludes any meaningful evaluation of the potential clinical benefit attriieble to tiro6ban. A large randomized trial of chical efkacy Ah weight adjustment of cooaxnitant heparin dosing is underway. 
